EP Patent

EP1785145A1 — Transnasal composition having immediate action and high absorbability

Assigned to Shin Nippon Biomedical Laboratories Ltd · Expires 2007-05-16 · 19y expired

What this patent protects

Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.

USPTO Abstract

Powdery compositions for intranasal administration, which comprise non-peptide/non-protein drugs and as a carrier, crystalline cellulose aggregates having a particular cribriform particle diameter, yield rapid action and high absorbability of the drugs.

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: EP1785145A1
Jurisdiction: EP
Classification: —
Expires: 2007-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Shin Nippon Biomedical Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.